Directory
Portfolio companies.
21,000+ PE-backed.
Active investments and exits across European private equity portfolios.
Filter by sector, geography, status. Find the right deal comp in seconds.
Active deals
918
currently held
Exits tracked
338
hand-checked
Sectors covered
1
across the portfolio
Countries covered
35
from every market
1,149 companies matching · Page 1 of 23
Tubulis
Health for Life Capital II
FranceSector
Biotech
InvestorSeventure Partners
Entry
2020
Hold
6yr
Owners
6
Agomab Therapeutics
Boehringer Ingelheim Venture Fund
BelgiumSector
Biotech
InvestorBoehringer Ingelheim Venture Fund
Entry
2019
Hold
7yr
Owners
3
Exit
2026
Akamis Bio
IP Group (Evergreen)
UKSector
Biotech
InvestorIP Group
Entry
2012
Hold
14yr
Owners
3
AgoMab
Sabadell Asabys Health Innovation Investments
FranceSector
Biotech
InvestorAsabys Partners
Entry
2019
Hold
7yr
Owners
2
Exit
2026
Memo Therapeutics
Ysios BioFund III
CHSector
Biotech
InvestorYsios Capital Partners
Entry
2018
Hold
8yr
Owners
2
Exit
2026
PathoQuest
Capital Santé 2
FranceSector
Biotech
InvestorTurenne Groupe
Entry
2021
Hold
5yr
Owners
2
Avalyn Pharma
BioDiscovery 5
FranceSector
Biotech
InvestorAndera Partners
Entry
2017
Hold
9yr
Exit
2026
Dark Blue Therapeutics
Oxford Science Enterprises Balance Sheet
UKSector
Biotech
InvestorOxford Science Enterprises
Entry
2020
Hold
6yr
Exit
2026
Soleno Therapeutics
Abingworth Bioventures VI
USSector
Biotech
InvestorAbingworth
Entry
2018
Hold
8yr
Exit
2026
Chain Biotechnology
UK Innovation and Science Seed Fund
UKSector
Biotech
InvestorFuture Planet Capital
Entry
2017
Hold
9yr
Exit
2026
Pantherna Therapeutics
HTGF III
GermanySector
Biotech
InvestorHigh-Tech Gruenderfonds (HTGF)
Entry
2019
Hold
7yr
Exit
2026
Congenica
Parkwalk Opportunities EIS Fund
UKSector
Biotech
InvestorParkwalk Advisors
Entry
2014
Hold
11yr
Owners
3
Exit
2025
Navan
HTGF III
United StatesSector
Biotech
InvestorHigh-Tech Gruenderfonds (HTGF)
Entry
2019
Hold
7yr
Owners
3
Verona Pharma
Sofinnova Crossover Fund I
United KingdomSector
Biotech
InvestorSofinnova Partners
Entry
2016
Hold
6yr
Owners
3
Exit
2025
Evommune
Oscar & Paul Venture Capital Fund I
FranceSector
Biotech
InvestorOscar & Paul (Beiersdorf Venture Capital)
Entry
2021
Hold
4yr
Owners
2
Exit
2025
Imcheck
BioDiscovery 6
FranceSector
Biotech
InvestorAndera Partners
Entry
2020
Hold
5yr
Owners
2
Exit
2025
Kalsiom
AFB Seed-Fund
FranceSector
Biotech
InvestorAdBio Partners
Entry
2020
Hold
6yr
Owners
2
Araris Biotech
4BIO Ventures II
SwitzerlandSector
Biotech
Investor4Bio Partners
Entry
2020
Hold
5yr
Exit
2025
Believer Meats
Cibus Fund II
Israel
Sector
Biotech
InvestorCibus Capital
Entry
2021
Hold
4yr
Exit
2025
Biocrates
MIG Fonds 16
AustriaSector
Biotech
InvestorMIG Capital
Entry
2019
Hold
6yr
Exit
2025
CureVac
dievini Hopp BioTech holding (Evergreen Balance Sheet)
GermanySector
Biotech
Investordievini Hopp BioTech holding
Entry
2005
Hold
20yr
Exit
2025
Evergreen Theragnostics
LIFTT
United StatesSector
Biotech
InvestorLIFTT
Entry
2024
Hold
1yr
Exit
2025
Officinae Bio
Nucleus Capital I
ItalySector
Biotech
InvestorNucleus Capital
Entry
2021
Hold
4yr
Exit
2025
Scorpion Therapeutics
Abingworth Bioventures VII
USSector
Biotech
InvestorAbingworth
Entry
2020
Hold
5yr
Exit
2025
Capstan Therapeutics
Mubadala Capital Other Investments
USASector
Biotech
InvestorMubadala Capital
Entry
2022
Hold
4yr
Owners
2
Kojin Therapeutics
Cathay Health
United StatesSector
Biotech
InvestorCathay Capital
Entry
2021
Hold
4yr
Owners
2
Exit
2025
Medsenic
Cap Innov'Est 1
FranceSector
Biotech
InvestorCapital Grand Est
Entry
2016
Hold
10yr
Owners
2
A3P Biomedical
Flerie Invest
SwedenSector
Biotech
InvestorFlerie
Entry
2022
Hold
3yr
Exit
2025
CARGO Therapeutics
Novo Holdings Venture Investments
United StatesSector
Biotech
InvestorNovo Holdings
Entry
2024
Hold
1yr
Exit
2025
Dorian Therapeutics
Vento Fund I
United StatesSector
Biotech
InvestorVento
Entry
2023
Hold
2yr
Exit
2025
EsoBiotec
Invivo Ventures
BelgiumSector
Biotech
InvestorInvivo Partners
Entry
2023
Hold
2yr
Exit
2025
GQ Bio Therapeutics
Innovationsstarter Fonds Hamburg I
GermanySector
Biotech
InvestorIFB Innovationsstarter
Entry
2012
Hold
13yr
Exit
2025
Inozyme Pharma
Novo Holdings Principal Investments
United StatesSector
Biotech
InvestorNovo Holdings
Entry
2023
Hold
2yr
Exit
2025
Stilla Technologies
LBO France Venture
FranceSector
Biotech
InvestorLBO France
Entry
2018
Hold
7yr
Exit
2025
Biobank
CAPZA 6 Private Debt
FranceSector
Biotech
InvestorCapza
Entry
2008
Hold
10yr
Owners
7
Amolyt Pharma
Sofinnova Crossover Fund I
FranceSector
Biotech
InvestorSofinnova Partners
Entry
2014
Hold
10yr
Owners
5
Exit
2024
Boundless Bio
Leaps by Bayer
United StatesSector
Biotech
InvestorLeaps by Bayer
Entry
2023
Hold
1yr
Exit
2024
Mablink Bioscience
Mérieux Innovation 1
FranceSector
Biotech
InvestorMerieux Equity Partners
Entry
2019
Hold
4yr
Owners
5
Exit
2024
Dynamic Biosensors
Seedfonds Bayern
GermanySector
Biotech
InvestorBayern Kapital
Entry
2012
Hold
12yr
Owners
3
Exit
2024
Cardior Pharmaceuticals
coparion
GermanySector
Biotech
Investorcoparion
Entry
2021
Hold
3yr
Owners
2
Exit
2024
DayTwo
Cathay Innovation Fund II
FranceSector
Biotech
InvestorCathay Capital
Entry
2017
Hold
7yr
Owners
2
FairJourney Biologics
Partners Group Direct Equity V
PortugalSector
Biotech
InvestorPartners Group
Entry
2020
Hold
4yr
Owners
2
STipe Therapeutics
Wellington Partners Life Sciences
DenmarkSector
Biotech
InvestorWellington Partners
Entry
2019
Hold
7yr
Owners
2
AptaTargets
Inveready Biotech II
SpainSector
Biotech
InvestorInveready Asset Management
Entry
2017
Hold
7yr
Exit
2024
BioData (Labguru)
Holtzbrinck Digital Balance Sheet
Israel
Sector
Biotech
InvestorHoltzbrinck Digital
Entry
2010
Hold
14yr
Exit
2024
CARDIOR
HTGF III
GermanySector
Biotech
InvestorHigh-Tech Gruenderfonds (HTGF)
Entry
2017
Hold
7yr
Exit
2024
Cytox Group
UK Innovation and Science Seed Fund
UKSector
Biotech
InvestorFuture Planet Capital
Entry
–
Exit
2024
Fusion Pharmaceuticals Inc.
HealthCap VII
Canada
Sector
Biotech
InvestorHealthCap
Entry
2017
Hold
7yr
Exit
2024
Metagenomi
Leaps by Bayer
United StatesSector
Biotech
InvestorLeaps by Bayer
Entry
2020
Hold
4yr
Exit
2024
Morphic Therapeutic
Novo Holdings Venture Investments
United StatesSector
Biotech
InvestorNovo Holdings
Entry
2023
Hold
1yr
Exit
2024